SiSaf is an RNA delivery and therapeutics company. Its proprietary Bio-Courier® technology addresses the limitations of other RNA delivery technologies through the hybridization of organic materials with inorganic bioabsorbable silicon.The company’s Bio-Courier portfolio includes silicon stabilized hybrid lipid nanoparticles (sshLNP) that improvethe stability, safety, and transfection efficiency of RNA. SiSaf uses sshLNP to develop a pipeline of RNA therapeutics for rare genetic disorders and is maximizing the potential of its technology through research partnerships.Led by founder and leading biomaterials specialist Dr Suzanne Saffie-Siebert, SiSaf is a venture capital backed private company. Headquartered in Guildford, UK, it has fully integrated research labs and bio-analytical facilities, a scalable technology to fast-track development, and a growing patent estate with extensive freedom to operate.

Pharmaceutical

Health Care

Biotechnology

SiSaf Ltd

Dr Suzanne Saffie-Siebert

Tim Brundle

Richard Scarrott

Nissim Torabi-Pour

John Stanton

Joanne Manson

Flavia M. Sutera

Charles Weatherstone

Andy Gibson

The Leadership Team at SiSaf Ltd is responsible for setting the strategic direction of the company, overseeing its operations, and ensuring alignment across various functions. Comprising key executives, including the Chairwoman & CEO, Chief Marketing Officer, Chief Technical Officer, and Chief Financial Officer, this team drives innovation in RNA delivery technologies, fosters partnerships, manages financial health, and promotes the company's mission in developing therapeutics for rare genetic disorders. Their combined expertise guides SiSaf's efforts to maximize the potential of its proprietary Bio-Courier® technology and advance the company's research and development goals.

Leadership Team

Operations Team

Research and Development

Leadership Team

About

Team members

Other teams at SiSaf Ltd

Operations Team

Research and Development